New research shines a light on an often-overlooked side of Huntington’s disease—psychosis. Understanding the impact of psychosis on daily life and progression of other HD symptoms could be key to providing better care and support.
New research suggests that cognitive engagement - keeping your brain busy with activities like reading, puzzles, or learning new skills - could help protect the brain, possibly slowing progression of symptoms of Huntington’s disease.
Apathy in Huntington’s disease isn’t just a lack of motivation—it’s a shift in how the brain weighs decisions. A new study sheds light on how targeted treatments could help restore motivation and improve quality of life.
A CRISPR-based approach called “base editing” is being explored to develop a new potential treatment for Huntington's disease. Editing a single letter in the genetic code with base editing may be the key for delaying HD symptoms, maybe by a decade.
The FDA has approved valbenazine, also known as INGREZZA, as a treatment for the movement symptoms of Huntington’s disease
In a much-needed bit of good news for the Huntington's disease community, Neurocrine Bioscience's KINECT-HD trial showed that treatment with valbenazine significantly reduced the involuntary movements called chorea
We know that HD-related changes can occur many years before symptom onset, but how early do those changes begin? A team of researchers set out to determine that with a new comprehensive study in pre-manifest HD young adults.
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease
HDBuzz helps untangle some bold claims about the just-announced results of the PRIDE-HD trial of pridopidine in HD
